AZD1775 continued access study to assess safety and tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

Trial Identifier: D6014C00007
Sponsor: AstraZeneca
Collaborator:
Quintiles, Inc.
NCTID:: NCT03313557
Start Date: October 2017
Primary Completion Date: May 2019
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
English Translation
Dutch Translation
French Translation

Trial Locations

Country Location
France Bordeaux Cedex, France, 33075
France Saint Herblain Cedex, France, 44805
Netherlands Amsterdam, Netherlands, 1066 CX
Netherlands Amsterdam, Netherlands, 1081 HV
Netherlands Maastricht, Netherlands, 6202 AZ
United Kingdom Glasgow, United Kingdom, G12 0YN
United Kingdom Manchester, United Kingdom, M20 4BX
United States of America, AZ Tucson, AZ, United States of America, 85724
United States of America, CA Los Angeles, CA, United States of America, 90048
United States of America, CA Pasadena, CA, United States of America, 91105
United States of America, MD Silver Spring, MD, United States of America, 20910
United States of America, MI Bingham Farms, MI, United States of America, 48025
United States of America, MI Detroit, MI, United States of America, 48202
United States of America, NH Lebanon, NH, United States of America, 03756
United States of America, OH Cincinnati, OH, United States of America, 45229
United States of America, RI Providence, RI, United States of America, 02903
United States of America, SC Greenville, SC, United States of America, 29605
United States of America, TX Dallas, TX, United States of America, 75251
United States of America, TX Houston, TX, United States of America, 77030